The study to explore the effecs of miglitol and sitagliptin on the responses of active gastric inhibitory polypeptide responses and the changes in body weight and visceral fat mass in type 2 diabetic patients with obesity

The study to explore the effecs of miglitol and sitagliptin on the responses of active gastric inhibitory polypeptide responses and the changes in body weight and visceral fat mass in type 2 diabetic patients with obesity - Miglitol And Sitagliptin on gasTric plypeptide sEcretory Responses in type 2 diabetic patients with obesity (MASTER Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006098

Enrollment

Registered

2011-08-02

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

miglitol 50 mg thrice a day sitagliptn once a day miglitol 50 mg thrice a day and sitgliptin 50 mg once a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. HbA1c < 10.4 % 2. BMI >= 25 3. diet therapy and/or exerxise thepapy with or without metformin on the conditions of 1 and 2 4. HbA1c <10.4 % and with low dose sulfonyl urea (glimepiride =< 2mg/day, glibenclamide =<1.25 mg/day or gliclazide =< 40 mg/day) on the conditions of 1 and 2

Exclusion criteria

Exclusion criteria: 1. type 1 diabetes 2. with severe or asymptomatic hypoglycemic episodes 3. severe hepatic disorders 4. with viral hepatitis 5. severe renal disease 6. severe heart failure or acute coronay syndrome within the previous 6 months 7. acute or chronic pancreatitis 8. malignant tumors 9. infectious diseases, under consideration of operations or with traumatic diseases 10. severe diabetc neuropathy 11. severe diabetic retinopathy 12. with ketoacidosis or severe hyperglycemic states 13. inflammatory bowel dideases, ileus or past history of ileus 14. chronic bowel diseases with malabsorption 15. with diseases which may grow worth by bowel gas retention 16. gastrectomy 17. lactose intolerance 18. massive alcohol intake 19. pregnacy, lactation or candidates 20. patients under ongoing other clinical trials or under those within 4 months 21. patients who are judged as inappropriate for inclusion by phsicians

Design outcomes

Primary

Measure	Time frame
Before and after administration of miglitol, sitagliptin or both 1. changes in plasma incretins 2. changes in body weight and visceral fat mass	—

Secondary

Measure	Time frame
HbA1c, 1,5-AG PYY, DHEAS	—

Countries

Japan

Contacts

Public ContactTakuma Narita

Akita University Garduate School of Medicine Department of Endocrinology, Diabetes and Geriatric Medicine

narita@med.akita-u.ac.jp+81-18-884-6769

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026